Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000)

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2895-2905

  Arnold, Kathryn B ^a   Hermos, John A ^b   Anderson, Karen B ^a   Minasian, Lori ^c   Tangen, Catherine M ^a   Probstfield, Jeffrey F ^d   Cook, Elise D ^e  

^a USA   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; SELENIUM;

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER PREVENTION; CAUCASIAN; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; RACE DIFFERENCE; RISK FACTOR; SMOKING; AFRICAN AMERICAN; FEMALE; METABOLISM; MIDDLE AGED; MINORITY GROUP; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MINORITY GROUPS; NEOPLASMS; SELENIUM; VITAMIN E;

EID: 84919394808     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0724     Document Type: Article

References (46)

1. Gadegbeku CA, Stillman PK, Huffman M.D., Jackson JS, Kusek JW, Jamerson KA. Factors associated with enrollment of African Americans into a clinical trial: results from the African American study of kidney disease and hypertension. Contemp Clin Trials 2008; 29: 837-42.
2. Mitchell EP. Prognostic impact of race and ethnicity in the treatment of colorectal cancer. Med Clin North Am 2005; 89: 1045-57, 54
3. Levkoff S, Sanchez H. Lessons learned about minority recruitment and retention from the Centers on minority aging and health promotion. Gerontologist 2003; 43: 18-26.
4. Brown DR, Topcu M. Willingness to participate in clinical treatment research among older African Americans and Whites. Gerontologist 2003; 43: 62-72.
5. Gorelick PB, Harris Y, Burnett B., Bonecutter FJ. The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc 1998; 90: 141-5.
6. Ford ME, Havstad SL, Tilley BC Recruiting older African American men to a cancer screening trial (the AAMEN Project). Gerontologist 2003; 43: 27-35.
7. Ford ME, Havstad SL, Fields M.E., Manigo B., McClary B, Lamerato L. Effects of baseline comorbidities on cancer screening trial adherence among older African American men. Cancer Epidemiol Biomarkers Prev 2008; 17: 1234-9.
8. Blumenthal DS, Sung J, Coates R., Williams J, Liff J. Recruitment and retention of subjects for a longitudinal cancer prevention study in an inner-city black community. Health Serv Res 1995; 30: 197-205.
9. Moinpour CM, Atkinson JO, Thomas S.M., Underwood SM, Harvey C, Parzuchowski J, et al Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol 2000; 10(8 Suppl):S85-91.
10. McCaskill-Stevens W., Wilson JW, Cook E.D., Edwards CL, Gibson RV, McElwain DL, et al National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. Clin Trials 2013; 10: 280-91.
11. Murthy VH, Krumholz HM, Gross CP Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-6.
12. Psaty BM, Cheadle A, Koepsell T.D., Diehr P., Wickizer T, Curry S, et al Race- and ethnicity-specific characteristics of participants lost to follow-up in a telephone cohort. Am J Epidemiol 1994; 140: 161-71.
13. Ford ME, Havstad S, Vernon S.W., Davis SD, Kroll D, Lamerato L, et al Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial. Gerontologist 2006; 46: 545-50.
14. Ofstedal MB, Weir DR Recruitment and retention of minority participants in the health and retirement study. Gerontologist 2011; 51 (SUPPL. 1):S8-20.
15. Jemal A, Murray T, Ward E., Samuels A, Tiwari RC, Ghafoor A, et al Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
16. Lippman SM, Goodman PJ, Klein E.A., Parnes HL, Thompson IM Jr, Kristal AR, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005; 97: 94-102.
17. Lippman SM, Klein EA, Goodman P.J., Lucia MS, Thompson IM, Ford LG, et al Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
18. Cook ED, Moody-Thomas S, Anderson K.B., Campbell R., Hamilton SJ, Harrington JM, et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials 2005; 2: 436-42.
19. Cook ED, Arnold KB, Hermos J.A., McCaskill-Stevens W, Moody-Thomas S, Probstfield J.L., et al. Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial. Clin Trials 2010; 7: 90-9.
20. Oddone EZ, Olsen MK, Lindquist J.H., Orr M., Horner R, Reda D, et al Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000). Control Clin Trials 2004; 25: 378-87.
21. Svensson CK. Representation of American blacks in clinical trials of new drugs. JAMA 1989; 261: 263-5.
22. Swanson GM, Ward AJ Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995; 87: 1747-59.
23. Probstfield JL, Frye RL Strategies for recruitment and retention of participants in clinical trials. JAMA 2011; 306: 1798-9.
24. Klein EA. SELECT: the selenium and vitamin E cancer prevention trial rationale and design. Prostate Cancer Prostatis Dis 2000; 3: 145-51.
25. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306: 1549-56.
26. Anderson GL, Limacher M, Assaf A.R., Bassford T., Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
27. Wactawski-Wende J., Kotchen JM, Anderson G.L., Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-96.
28. Hercberg S, Galan P, Preziosi P., et al. The su.vi.max study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164: 2335-42.
29. Thompson IM, Goodman PJ, Tangen C.M., Lucia MS, Miller GJ, Ford LG, et al The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
30. Ahmed I, Gugsa ST, Lemma S, Demissie M. Predictors of loss to follow-up before HIV treatment initiation in Northwest Ethiopia: a case control study. BMC Public Health 2013; 13:867.
31. Alvarez-Uria G., Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. Glob Health Action 2013; 6:21682.
32. Nishijima T, Gatanaga H, Komatsu H., Takano M, Ogane M, Ikeda K., et al. Illicit drug use is a significant risk factor for loss to follow-up in patients with HIV-1 infection at a large urban HIV clinic in Tokyo. PloS ONE 2013; 8:e72310.
33. Rice BD, Delpech VC, Chadborn T.R., Elford J. Loss to follow-up among adults attending human immunodeficiency virus services in England, Wales, and Northern Ireland. Sex Transm Dis 2011; 38: 685-90.
34. Merrill RM, Aldana SG Cardiovascular risk reduction and factors influencing loss to follow-up in the coronary health improvement project. Med Sci Monit 2008; 14:Ph17-25.
35. Lebouche B, Yazdanpanah Y, Gerard Y., Sissoko D, Ajana F, Alcaraz I., et al. Incidence rate and risk factors for loss to follow-up in a French clinical cohort of HIV-infected patients from January 1985 to January 1998. HIV Med 2006; 7: 140-5.
36. Dalle Grave R., Calugi S, Molinari E., Petroni ML, Bondi M, Compare A, et al Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res 2005; 13: 1961-9.
37. Zunzunegui MV, Beland F, Gutierrez-Cuadra P. Loss to follow-up in a longitudinal study on aging in Spain. J Clin Epidemiol 2001; 54: 501-10.
38. Blanker MH, Prins J, Bosch J.L., Schouten BW, Bernsen RM, Groeneveld FP, et al. Loss to follow-up in a longitudinal study on urogenital tract symptoms in Dutch older men. Urol Int 2005; 75: 30-7.
39. Lertsithichai P, Pornchai S. Factors influencing loss to follow-up after elective inguinal herniorrhaphy. J Med Assoc Thai 2012; 95: 37-41.
40. 2 years. Am J Epidemiol 1995; 142: 323-30.
41. Krishnan S, Wu K, Smurzynski M., Bosch RJ, Benson CA, Collier AC, et al Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials 2011; 12: 190-200.
42. Murphy AB, Akereyeni F, Nyame Y.A., Guy MC, Martin IK, Hollowell CM, et al Smoking and prostate cancer in a multi-ethnic cohort. Prostate 2013; 73: 1518-28.
43. National Center for Health Statistics. Health, United States, 2005 with Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2005.
44. Coatsworth JD, Duncan LG, Pantin H, Szapocznik J. Patterns of retention in a preventive intervention with ethnic minority families. J Prim Prev 2006; 27: 171-93.
45. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/ Latinos, 2012. CA Cancer J Clin 2012; 62: 283-98.
46. Minasian LM, Carpenter WR, Weiner B.J., Anderson DE, McCaskill-Stevens W, Nelson S, et al Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer 2010; 116: 4440-9.